ArticleAIDS and behavior2023
Women Want Choices: Opinions from the Share.Learn.Shape Global Internet Survey About Multipurpose Prevention Technology (MPT) Products in Development.
Article in AIDS and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- A Dual Prevention Pill for HIV & Pregnancy Prevention: A Pilot Study Among Adolescent Girls and Young Women in Zimbabwe.AIDS and behavior · 2026Trial
- Article
- Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention.Microbiology spectrum · 2026Article
- Formulation Development of Topical Inserts Containing Doxycycline and Doxycycline Combined with Tenofovir Alafenamide and Elvitegravir for the Prevention of Sexually Transmitted Infections.AAPS PharmSciTech · 2026Article
- Multipurpose vaginal rings: preferences from a national discrete choice experiment survey among US women.Frontiers in reproductive health · 2026Article
- Bioresponsive Hydrogel for On-Demand Nonhormonal Contraception.Gels (Basel, Switzerland) · 2025Article
- Acceptability of and preferences for long-acting injectable hormonal contraception among US women: evidence from a national cross-sectional online survey.Contraception and reproductive medicine · 2025Article
- Factors associated with women's preference for an over-encapsulated Dual Prevention Pill: Findings from two clinical crossover trials among women in South Africa and Zimbabwe.Research square · 2025Article
- "…this could be a noble idea and a game changer." The potential of a dual prevention pill for HIV and pregnancy prevention among adolescent girls and young women in Zimbabwe.PLOS global public health · 2025Article
- Article
- Ending HIV Transmission in Australia: Expanding PrEP to Cisgender Women: A Scoping Review.AIDS and behavior · 2024Article
- "Killing two birds with one stone" - a qualitative study on women's perspectives on the dual prevention pill in Johannesburg, South Africa.BMC women's health · 2024Article
- Perception of couples' on multipurpose prevention technology attribute choice: the case of MTN 045.BMC public health · 2024Article
- Article
- Prevention method preferences and factors influencing hypothetical choice among women in South Africa: a survey exploring opportunities for a multipurpose prevention technology implant.Frontiers in reproductive health · 2024Article
- Editorial: Multipurpose prevention technologies for HIV, STIs and pregnancies.Frontiers in reproductive health · 2024Article
- Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.Journal of the International AIDS Society · 2023Article
- Synthesis of end-user research to inform future multipurpose prevention technologies in sub-Saharan Africa: a scoping review.Frontiers in reproductive health · 2023Article
- Biomedical, socio-behavioral, and implementation science gaps in multipurpose prevention technology research.Frontiers in reproductive health · 2023Article
- Program impact and potential pitfalls of multi-purpose technologies (MPTs) for HIV prevention and contraception.Frontiers in reproductive health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Women need multipurpose prevention technologies (MPTs) to simultaneously prevent sexually transmitted infections (STIs), including HIV, with or without contraception. User feedback early in product development is critical for maximizing uptake and continuation. Our global online survey (April 2017-December 2018) explored women's opinions about MPT formulations in development (e.g., fast-dissolving vaginal inserts, vaginal films, intravaginal rings, injectables, implants), preferences for long-acting or "on-demand" methods, and interest in a contraceptive MPT versus products for HIV/STI prevention alone. Of the 630 women in our final analysis (mean 30 years old; range 18-49), 68% were monogamous, 79% completed secondary education, 58% had ≥ 1 child, 56% were from sub-Saharan Africa and 82% preferred a cMPT versus HIV/STI prevention alone. There were no clear preferences for any specific product or product type (long-acting, on-demand, daily). No single product will appeal everyone, however, adding contraception is likely to increase uptake of HIV/STI prevention methods for most women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.